Loading...
XJPX
4527
Market cap3.15bUSD
May 28, Last price  
2,020.00JPY
1D
-0.79%
1Q
-8.12%
Jan 2017
119.80%
Name

Rohto Pharmaceutical Co Ltd

Chart & Performance

D1W1MN
XJPX:4527 chart
No data to show
P/E
14.75
P/S
1.69
EPS
136.91
Div Yield, %
1.53%
Shrs. gr., 5y
—
Rev. gr., 5y
8.08%
Revenues
270.84b
+13.48%
108,206,000,000110,601,000,000113,430,000,000115,262,000,000120,423,000,000128,666,000,000144,082,000,000151,994,000,000166,477,000,000154,599,000,000171,795,000,000183,672,000,000188,375,000,000181,053,000,000199,646,000,000238,664,000,000270,840,000,000
Net income
30.94b
+17.28%
7,525,000,0006,139,000,0007,768,000,0007,966,000,0008,184,000,0008,087,000,0008,947,000,0008,631,000,0009,098,000,00010,011,000,0009,289,000,0009,799,000,00015,410,000,00016,743,000,00021,127,000,00026,377,000,00030,936,000,000
CFO
34.25b
+10.74%
12,610,000,0007,364,000,00015,094,000,00012,924,000,00010,391,000,00016,702,000,00018,661,000,00011,292,000,00011,324,000,00013,428,000,00019,154,000,00021,745,000,00019,040,000,00020,008,000,00027,250,000,00030,924,000,00034,245,000,000
Dividend
Sep 29, 20250 JPY/sh
Earnings
Aug 05, 2025

Profile

Rohto Pharmaceutical Co.,Ltd. manufactures and markets pharmaceutical products, cosmetics, and functional foods worldwide. The company provides eye care products, such as eye drops, care for contact lenses, and eye wash; and facial care products comprising face wash, lotions, and creams. It also offers medicine and medicated products for skin; medicine for internal use, such as digestive and herbal medicines; oral medicines comprising gastrointestinal medicines, herbal medicines, and supplements; non-prescription medicines; and beauty counters that provide beauty and health services. The company was formerly known as Yamada Pharmaceutical and changed its name to Rohto Pharmaceutical Co.,Ltd. in September 1949. Rohto Pharmaceutical Co.,Ltd. was founded in 1899 and is headquartered in Osaka, Japan.
URL
https://www.rohto.co.jp/
IPO date
Oct 02, 1961
Employees
7,176
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFY
2024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑032016‑03
Income
Revenues
270,840,000
13.48%
238,664,000
19.54%
Cost of revenue
226,656,000
158,775,000
Unusual Expense (Income)
NOPBT
44,184,000
79,889,000
NOPBT Margin
16.31%
33.47%
Operating Taxes
10,123,000
7,860,000
Tax Rate
22.91%
9.84%
NOPAT
34,061,000
72,029,000
Net income
30,936,000
17.28%
26,377,000
24.85%
Dividends
(5,475,000)
(4,676,000)
Dividend yield
0.81%
0.74%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
1,052,000
4,177,000
Long-term debt
6,688,000
8,700,000
Deferred revenue
3,146,000
Other long-term liabilities
5,268,000
2,604,000
Net debt
(125,201,000)
(99,703,000)
Cash flow
Cash from operating activities
34,245,000
30,924,000
CAPEX
(7,979,000)
(9,908,000)
Cash from investing activities
(16,317,000)
(13,176,000)
Cash from financing activities
(13,784,000)
(16,199,000)
FCF
38,079,000
59,838,000
Balance
Cash
89,210,000
79,951,000
Long term investments
43,731,000
32,629,000
Excess cash
119,399,000
100,646,800
Stockholders' equity
247,456,000
214,722,000
Invested Capital
143,396,000
125,642,200
ROIC
25.32%
59.55%
ROCE
16.71%
35.12%
EV
Common stock shares outstanding
228,798
228,798
Price
2,967.00
7.11%
2,770.00
49.93%
Market cap
678,843,666
7.11%
633,770,460
49.93%
EV
554,352,666
539,575,460
EBITDA
52,871,000
87,690,000
EV/EBITDA
10.49
6.15
Interest
196,000
247,000
Interest/NOPBT
0.44%
0.31%